{"name":"ArriVent BioPharma, Inc.","slug":"arrivent-biopharma-inc","ticker":"","exchange":"","domain":"arrivent.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNNHBZdW9IMGdZb1FreDFuVF92UDRYT3J0eFdpWU5Kdzg1eTh6c1VQRDR6UWYxT3Mwdm9VUDhBdEFWLWR0MkdDRFd0Q1VhSTM2WURMdDJ0Qi05azZXUFgyUXJ2dUpSb3JJSUxjcVlQaWdrUTBJWFJISHRRU29VZlFnRmd5R0RCX3NWYjlDc0hTVGJvb2hTRVFIMG5NWk9NaEtlWXlLaWMyaEVSZFVTSzF2UEMzYmo5UnFPTF81MA?oc=5","date":"2026-03-24","type":"trial","source":"Seeking Alpha","summary":"ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha","headline":"ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcThKX3RaWWVBdUstTGp0ZmhUN241bXJOQ1dUU3ZNTENzUDRUcmM3dWZyVXc4VlFDYVM3aXZlRXA2d0xRY3F5cXhudDJqeUY0NTZlMVhfUUNya0ZKNERUOVBXczhvTDVVWE9zRkxVNFA5aFV5eGJWdjVGazRmcXIxTnZZM0tldWFPT0RFZ0l3X1VXTEJBVnM3c3V4cWtfWk1PMXVQRXFPUGJObUZsRm1MUXF3dw?oc=5","date":"2026-03-17","type":"trial","source":"Stock Titan","summary":"ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan","headline":"ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPVUlEOWpxZEhpeGZraTRCR0l1bUlNM3VyaFpOZ3FXUXZ3akd5NjNpYWIxU20zRjV1Y3lMZVFLV0NIaUFQcGlma3pycWpSQnI0dWVtMU1fLXFtQ3owV3dyNWRFU1ZWTEtVRkRRenRjc1JBeU4zUnpOWi1VZWxwQVVFdW9RNXdfbzQwc2p3bDMtS1NiNFlhOUhEdUdnQmpPenZUTk5rLS1NRG45NG5lOFZTS2VVMA?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"ArriVent BioPharma (NASDAQ: AVBP) widens 2025 loss as R&D spend climbs - Stock Titan","headline":"ArriVent BioPharma (NASDAQ: AVBP) widens 2025 loss as R&D spend climbs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPektpTnpLTDV2OXNXMWplaWIzQld2MElIVWF3T05xeFVFbkZXLTRIcDRlQ3FMbGZfQkpEWm0yVUxWNUhjeXJlc1Q0cEw3SHY1Q1VUZGhUNHdHS20tTXZhc0NpbXktb1JmSHlPRGhZMmRzVUNpRnpTWTdvNmhEN3U0MTRrMTVwRHpKS01QT3pyMmZKVGh5MGpTVVllNEhuWmdDZEE0OHNlclVWTnoya3M1SHFob0N3TlNoZVF5TlVZM1p2eUNpUmhhSHdUYw?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"Sofinnova entities report 1.70M shares in ArriVent Biopharma (AVBP) - Stock Titan","headline":"Sofinnova entities report 1.70M shares in ArriVent Biopharma (AVBP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOYWpqSmpBUzRISldYQlIwU1pXR1VzbHhxU05mdksyc29zRkpJOEJIVm5vSUUyNFZ1aWptQ216WU5VNXJ1cWJUdHRJbVR1T1RxSDg3VGYzeFlfTUJGNkVtbWxQMjcyemtBMzlMemxuVDRfS2IyU3NQU2NzQU1hT3JzMkdmUXBvUUszTUZpOHI4czQ0U19MZDNocnVvTEZzOFJSZWp6bElhNGpfRGRkd1E?oc=5","date":"2026-01-04","type":"deal","source":"Seeking Alpha","summary":"ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha","headline":"ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-13","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNLVpXSUJxbkZydFljR21iTXJhMDYwd2hzUDZfUnpMNDVNbWhGdWNON2RMOERjOExfZmYwelBJa05WZ0lCVmM0Q2xmWEJPcGJXMC1IdmVERlJkWUFOTnl0OVlvZmFZUmR5MEhycWI2WjBwczVQQzdZT3hWR3hPWXpaREFheHNZX0RTVmlyM3ZoSVpXTXdjZmFuR2NETjB1ZV81ZkIw?oc=5","date":"2025-06-23","type":"trial","source":"Mugglehead Magazine","summary":"Citi boosts share target for ArriVent BioPharma by US$4 on positive trial data - Mugglehead Magazine","headline":"Citi boosts share target for ArriVent BioPharma by US$4 on positive trial data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOVFFuc3l4WnRlZWhxbTBabGlhNlJ0c3ZkREdxaTJOS05jSE5jOVBjN2FpOFd2anVNbjNLeVNDalJDNldmN0d5WXJQSmh3OWtLaXRlbm9mOHlaczZLcTRtcVZmdkt6SVFFMFpNM0Rad1VxQjlwYnhnbmdTWkVMX28ybUR6WHlYSV9sVnNEU0lZZmVFQjFBR3dmN05iUVZvc2xrcTU1QkVzOXRyM0lwdmwyQmoycmx6dw?oc=5","date":"2025-01-22","type":"pipeline","source":"Fierce Biotech","summary":"ArriVent continues to bulk out ADC pipeline, paying Lepu $47M for preclinical GI asset - Fierce Biotech","headline":"ArriVent continues to bulk out ADC pipeline, paying Lepu $47M for preclinical GI asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQcXNyNVJpTGxXdTEyYmtKU045X3c1a1hTQUNnaEgzQTN2VzRpQ21Uc0ZZM1Z4eFhlVEw1d1JsVkJwNWhxS3VsZDRQVkVrTHZUS1l4LW9vdFlLdUJDdktUQlVVWHdDOUd5Q3JrUHlqemNWZ0JwVV82cTRudWRUX08zUF9lb0RqaWRWczd1VWZ4d2xlTkljY2lDSWowYXE?oc=5","date":"2024-09-09","type":"trial","source":"Oncology Pipeline","summary":"World Lung 2024 – ArriVent looks for lung cancer white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"World Lung 2024 – ArriVent looks for lung cancer white space | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1BTUphTEdYVnBIRVk0MjRTLXpINkhPaUJ5OTljOXF1VEEweXJEUG9jQnhPZTdVQm56R2J3ZDJFMzRSZmxaaFMxdGRobEFDSnE2eWc?oc=5","date":"2024-03-06","type":"pipeline","source":"Yahoo Finance Singapore","summary":"ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history - Yahoo Finance Singapore","headline":"ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxORk00REh6bk96SGVUS2NOSkl3QkJNdzVmZ3FXRnI5Y0JkSUdIbkxtZEtmUkhDNjI5OUh1d19LRl9FUDhZUUJCbUd3Q2E5UGY3WG1Sa014c3FPT0FhU3N2YklzNVRGZEZwTjJCaG9FQ3FLTS1PazRaTVpyV2Vua0VuQ1FmYmo0eE5FU3JtdlU1Zw?oc=5","date":"2024-01-25","type":"pipeline","source":"BioPharma Dive","summary":"Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO - BioPharma Dive","headline":"Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOTGg2V1NhRUk0Qk53a2Z0Z2hEOFZkZXhkUUU4dk9HZzZ6T2prVjhVRXFQOGN1aHl5TmJBZUpfdzJxYVVzQ2FOa3JlMTlqdEpia1d5SmN5dTFCVnlKM2g5Y0lWNHFKU2lzb2daakZWZ295Q1h6WnFZcXhrN3pGN1k0dExRUUh4VUtMRzBqQWhBLUJjeDZ2MzFqdGVOWUdsTjRsV3J3MUFDQTZwT3JTNmR0bUVWYTRMRVUtcmdnWUhoTjdJMXFxdzFCaW10OFg1QXppeE9pai1oc2xnVWV6em9sNEl5QmhhQ3dsbGNPd3BRV2xKQ1RKdWtiRHBXVGEyRHg1djFsYUtob3JENUpTTVZQREJKQUk0ekhEUTJ6U2ZLcEhMZjBVdjJIM1VXeE9Cdw?oc=5","date":"2021-06-30","type":"pipeline","source":"GlobeNewswire","summary":"ArriVent Biopharma Launches with Up To $150M in Series A - GlobeNewswire","headline":"ArriVent Biopharma Launches with Up To $150M in Series A","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}